Proposed Registration Decision PRD2021-03, Fluazaindolizine and Salibro Nematicide
This Summary describes the key points of the evaluation, while the Science evaluation of Proposed Registration Decision PRD2021-03, Fluazaindolizine and Salibro Nematicide provides detailed technical information on the human health, environmental and value assessments of fluazaindolizine and Salibro Nematicide.
- Publisher - Current Organization Name: Health Canada
- Licence: Open Government Licence - Canada
Data and Resources
-
Proposed Registration Decision PRD2021-03, Fluazaindolizine and Salibro NematicideHTMLEnglish publication HTML
-
Proposed Registration Decision PRD2021-03, Fluazaindolizine and Salibro NematicideHTMLFrench publication HTML
Similar records